Molecular Partners Provides Regulatory Update of European and Japanese Filings of Abicipar Pegol
Zurich-Schlieren, Switzerland, July 20, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage
biotech company that is developing a new class of custom-built proteins known as DARPin®
therapeutics, today announced that Allergan, an AbbVie company, has informed Molecular Partners
of their intent to withdraw application filings with both the European Medicines Agency (EMA) and
the Japanese Regulatory Agency (PMDA) for abicipar pegol, a novel DARPin therapeutic for patients
with neovascular (wet) age-related macular degeneration (nAMD).
Following the recent decision from the U.S. Food and Drug Administration (FDA), AbbVie is
committed to working with the regulatory agencies to determine the appropriate next steps and
discuss requirements for potential resubmissions for abicipar pegol. The company continues to
believe in the need for new treatment options for nAMD.